Ballering, A. V., van Zon, S. Ok. R., Hartman, T. C. O. & Rosmalen, J. G. M. Persistence of somatic signs after COVID-19 within the Netherlands: an observational cohort examine. Lancet 400, 452–461 (2022).
Bull-Otterson, L. Submit–COVID situations amongst grownup COVID-19 survivors aged 18–64 and ≥65 years — United States, March 2020–November 2021. MMWR Morb. Mortal. Wkly Rep. 71, 713 (2022).
Ceban, F. et al. Fatigue and cognitive impairment in post-COVID-19 syndrome: a scientific overview and meta-analysis. Mind Behav. Immun. 101, 93–135 (2022).
Al-Aly, Z., Bowe, B. & Xie, Y. Lengthy COVID after breakthrough SARS-CoV-2 an infection. Nat. Med. (2022).
Ayoubkhani, D. et al. Threat of Lengthy Covid in individuals contaminated with SARS-CoV-2 after two doses of a COVID-19 vaccine: community-based, matched cohort examine. Preprint at medRxiv (2022).
FAIR Well being. Sufferers Identified with Submit-COVID Circumstances: An Evaluation of Personal Healthcare Claims Utilizing the Official ICD-10 Diagnostic Code (FAIR Well being, 2022).
Davis, H. E. et al. Characterizing lengthy COVID in a global cohort: 7 months of signs and their affect. eClinicalMedicine 38, 101019 (2021).
Xie, Y., Xu, E., Bowe, B. & Al-Aly, Z. Lengthy-term cardiovascular outcomes of COVID-19. Nat. Med. 28, 583–590 (2022).
Xie, Y. & Al-Aly, Z. Dangers and burdens of incident diabetes in lengthy COVID: a cohort examine. Lancet Diabetes Endocrinol. 10, 311–321 (2022).
Mancini, D. M. et al. Use of cardiopulmonary stress testing for sufferers with unexplained dyspnea submit–coronavirus illness. JACC Coronary heart Fail. 9, 927–937 (2021).
Kedor, C. et al. A potential observational examine of post-COVID-19 power fatigue syndrome following the primary pandemic wave in Germany and biomarkers related to symptom severity. Nat. Commun. 13, 5104 (2022).
Larsen, N. W. et al. Characterization of autonomic symptom burden in lengthy COVID: a world survey of 2314 adults. Entrance. Neurol. 13, 1012668 (2022).
Demko, Z. O. et al. Submit-acute sequelae of SARS-CoV-2 (PASC) affect high quality of life at 6, 12 and 18 months post-infection. Preprint at medRxiv (2022).
Cairns, R. & Hotopf, M. A scientific overview describing the prognosis of power fatigue syndrome. Occup. Med. Oxf. Engl. 55, 20–31 (2005).
Bach, Ok. Is ‘lengthy Covid’ worsening the labor scarcity? Brookings (2022).
Swank, Z. et al. Persistent circulating extreme acute respiratory syndrome coronavirus 2 spike is related to post-acute coronavirus illness 2019 sequelae. Clin. Infect. Dis. (2022).
Proal, A. D. & VanElzakker, M. B. Lengthy COVID or post-acute sequelae of COVID-19 (PASC): an outline of organic components which will contribute to persistent signs. Entrance. Microbiol. 12, 698169 (2021).
Klein, J. et al. Distinguishing options of Lengthy COVID recognized by way of immune profiling. Preprint at medRxiv (2022).
Glynne, P., Tahmasebi, N., Gant, V. & Gupta, R. Lengthy COVID following delicate SARS-CoV-2 an infection: attribute T cell alterations and response to antihistamines. J. Investig. Med. 70, 61–67 (2022).
Phetsouphanh, C. et al. Immunological dysfunction persists for 8 months following preliminary mild-to-moderate SARS-CoV-2 an infection. Nat. Immunol. 23, 210–216 (2022).
Zubchenko, S., Kril, I., Nadizhko, O., Matsyura, O. & Chopyak, V. Herpesvirus infections and post-COVID-19 manifestations: a pilot observational examine. Rheumatol. Int. (2022).
Peluso, M. J. et al. Proof of current Epstein-Barr virus reactivation in people experiencing Lengthy COVID. Preprint at medRxiv (2022).
Yeoh, Y. Ok. et al. Intestine microbiota composition displays illness severity and dysfunctional immune responses in sufferers with COVID-19. Intestine 70, 698–706 (2021).
Liu, Q. et al. Intestine microbiota dynamics in a potential cohort of sufferers with post-acute COVID-19 syndrome. Intestine 71, 544–552 (2022).
Mendes de Almeida, V. Intestine microbiota from sufferers with delicate COVID-19 trigger alterations in mice that resemble post-COVID syndrome. Res. Sq. (2022).
Wallukat, G. et al. Useful autoantibodies towards G-protein coupled receptors in sufferers with persistent long-COVID-19 signs. J. Transl Autoimmun. 4, 100100 (2021).
Su, Y. et al. A number of early components anticipate post-acute COVID-19 sequelae. Cell 185, 881–895.e20 (2022).
Arthur, J. M. et al. Improvement of ACE2 autoantibodies after SARS-CoV-2 an infection. PLoS ONE 16, e0257016 (2021).
Haffke, M. et al. Endothelial dysfunction and altered endothelial biomarkers in sufferers with post-COVID-19 syndrome and power fatigue syndrome (ME/CFS). J. Transl Med. 20, 138 (2022).
Charfeddine, S. Lengthy COVID 19 syndrome: is it associated to microcirculation and endothelial dysfunction? Insights from TUN-EndCOV examine. Entrance. Cardiovasc. Med. (2021).
Pretorius, E. et al. Prevalence of signs, comorbidities, fibrin amyloid microclots and platelet pathology in people with Lengthy COVID/post-acute sequelae of COVID-19 (PASC). Cardiovasc. Diabetol. 21, 148 (2022).
Spudich, S. & Nath, A. Nervous system penalties of COVID-19. Science 375, 267–269 (2022).
Renz-Polster, H., Tremblay, M.-E., Bienzle, D. & Fischer, J. E. The pathobiology of myalgic encephalomyelitis/power fatigue syndrome: the case for neuroglial failure. Entrance. Cell. Neurosci. 16, 888232 (2022).
Merzon, E. et al. Scientific and socio-demographic variables related to the analysis of lengthy COVID syndrome in youth: a population-based examine. Int. J. Environ. Res. Public Well being 19, 5993 (2022).
CDC. Lengthy COVID – family pulse survey – COVID-19. CDC (2022).
Williamson, A. E., Tydeman, F., Miners, A., Pyper, Ok. & Martineau, A. R. Quick-term and long-term impacts of COVID-19 on financial vulnerability: a population-based longitudinal examine (COVIDENCE UK). BMJ Open 12, e065083 (2022).
Ziauddeen, N. et al. Traits and affect of Lengthy Covid: findings from a web based survey. PLoS ONE 17, e0264331 (2022).
Choutka, J., Jansari, V., Hornig, M. & Iwasaki, A. Unexplained post-acute an infection syndromes. Nat. Med. 28, 911–923 (2022).
Komaroff, A. L. & Lipkin, W. I. Insights from myalgic encephalomyelitis/power fatigue syndrome could assist unravel the pathogenesis of postacute COVID-19 syndrome. Tendencies Mol. Med. 27, 895–906 (2021).
Schultheiß, C. et al. From on-line knowledge assortment to identification of illness mechanisms: the IL-1ß, IL-6 and TNF-α cytokine triad is related to post-acute sequelae of COVID-19 in a digital analysis cohort. SSRN (2021).
Peluso, M. J. et al. Markers of immune activation and irritation in people with postacute sequelae of extreme acute respiratory syndrome coronavirus 2 an infection. J. Infect. Dis. 224, 1839–1848 (2021).
Fernández-Castañeda, A. et al. Gentle respiratory SARS-CoV-2 an infection could cause multi-lineage mobile dysregulation and myelin loss within the mind. Preprint at bioRxiv (2022).
Hornig, M. et al. Distinct plasma immune signatures in ME/CFS are current early in the midst of sickness. Sci. Adv. 1, e1400121 (2015).
Wang, E. Y. et al. Various purposeful autoantibodies in sufferers with COVID-19. Nature 595, 283–288 (2021).
Shikova, E. et al. Cytomegalovirus, Epstein-Barr virus, and human herpesvirus-6 infections in sufferers with myalgic еncephalomyelitis/power fatigue syndrome. J. Med. Virol. 92, 3682–3688 (2020).
Schreiner, P. et al. Human herpesvirus-6 reactivation, mitochondrial fragmentation, and the coordination of antiviral and metabolic phenotypes in myalgic encephalomyelitis/power fatigue syndrome. Immunohorizons 4, 201–215 (2020).
García-Abellán, J. et al. Antibody response to SARS-CoV-2 is related to long-term scientific end result in sufferers with COVID-19: a longitudinal examine. J. Clin. Immunol. 41, 1490–1501 (2021).
Augustin, M. et al. Submit-COVID syndrome in non-hospitalised sufferers with COVID-19: a longitudinal potential cohort examine. Lancet Reg. Well being Eur. 6, 100122 (2021).
Talla, A. et al. Longitudinal immune dynamics of delicate COVID-19 outline signatures of restoration and persistence. Preprint at bioRxiv (2021).
Peluso, M. J. et al. Lengthy-term SARS-CoV-2-specific immune and inflammatory responses in people recovering from COVID-19 with and with out post-acute signs. Cell Rep. 36, 109518 (2021).
Hu, F. et al. A compromised particular humoral immune response towards the SARS-CoV-2 receptor-binding area is expounded to viral persistence and periodic shedding within the gastrointestinal tract. Cell. Mol. Immunol. 17, 1119–1125 (2020).
Korte, W. et al. SARS-CoV-2 IgG and IgA antibody response is gender dependent; and IgG antibodies quickly decline early on. J. Infect. 82, e11–e14 (2021).
Jo, W. et al. A two-phase, single cohort examine of COVID-19 antibody sera-surveillance. Ann. Epidemiol. Public Well being 4, 1055 (2021).
Nomura, Y. et al. Attenuation of antibody titers from 3 to six months after the second dose of the BNT162b2 vaccine depends upon intercourse, with age and smoking threat components for decrease antibody titers at 6 months. Vaccines 9, 1500 (2021).
Tejerina, F. et al. Submit-COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in sufferers with persistent signs after COVID-19. BMC Infect. Dis. 22, 211 (2022).
Goh, D. et al. Persistence of residual SARS-CoV-2 viral antigen and RNA in tissues of sufferers with lengthy COVID-19. Preprint at (2022).
Ceulemans, L. J. et al. Persistence of SARS-CoV-2 RNA in lung tissue after delicate COVID-19. Lancet Respir. Med. 9, e78–e79 (2021).
Gaebler, C. et al. Evolution of antibody immunity to SARS-CoV-2. Nature 591, 639–644 (2021).
Menuchin-Lasowski, Y. et al. SARS-CoV-2 infects and replicates in photoreceptor and retinal ganglion cells of human retinal organoids. Stem Cell Rep 17, 789–803 (2022).
Cheung, C. C. L. et al. Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from 5 recovered sufferers with COVID-19. Intestine 71, 226–229 (2022).
Natarajan, A. et al. Gastrointestinal signs and fecal shedding of SARS-CoV-2 RNA counsel extended gastrointestinal an infection. Med 3, 371–387.e9 (2022).
Katsoularis, I. et al. Dangers of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled circumstances collection and matched cohort examine. BMJ 377, e069590 (2022).
Pretorius, E. et al. Persistent clotting protein pathology in Lengthy COVID/post-acute sequelae of COVID-19 (PASC) is accompanied by elevated ranges of antiplasmin. Cardiovasc. Diabetol. 20, 172 (2021).
Kubánková, M. et al. Bodily phenotype of blood cells is altered in COVID-19. Biophys. J. 120, 2838–2847 (2021).
Osiaevi, I. et al. Persistent capillary rarefication in lengthy COVID syndrome. Angiogenesis (2022).
Patel, M. A. et al. Elevated vascular transformation blood biomarkers in long-COVID point out angiogenesis as a key pathophysiological mechanism. Mol. Med. 28, 122 (2022).
Puntmann, V. O. et al. Outcomes of cardiovascular magnetic resonance imaging in sufferers not too long ago recovered from coronavirus illness 2019 (COVID-19). JAMA Cardiol 5, 1265–1273 (2020).
Roca-Fernández, A. et al. Cardiac impairment in Lengthy Covid 1-year post-SARS-CoV-2 an infection. Eur. Coronary heart J. 43, ehac544.219 (2022).
Dennis, A. et al. Multiorgan impairment in low-risk people with post-COVID-19 syndrome: a potential, community-based examine. BMJ Open 11, e048391 (2021).
Dennis, A. et al. Multi-organ impairment and Lengthy COVID: a 1-year potential, longitudinal cohort examine. Preprint at medRxiv (2022).
Bowe, B., Xie, Y., Xu, E. & Al-Aly, Z. Kidney outcomes in Lengthy COVID. J. Am. Soc. Nephrol. 32, 2851–2862 (2021).
Almufarrij, I. & Munro, Ok. J. One yr on: an up to date systematic overview of SARS-CoV-2, COVID-19 and audio-vestibular signs. Int. J. Audiol. 60, 935–945 (2021).
Holdsworth, D. A. et al. Complete scientific evaluation identifies particular neurocognitive deficits in working-age sufferers with long-COVID. PLoS ONE 17, e0267392 (2022).
Cysique, L. A. et al. Submit-acute COVID-19 cognitive impairment and decline uniquely affiliate with kynurenine pathway activation: a longitudinal observational examine. Preprint at medRxiv (2022).
Crivelli, L. et al. Adjustments in cognitive functioning after COVID-19: a scientific overview and meta-analysis. Alzheimers Dement. 18, 1047–1066 (2022).
Woo, M. S. et al. Frequent neurocognitive deficits after restoration from delicate COVID-19. Mind Commun. 2, fcaa205 (2020).
Taquet, M. et al. Neurological and psychiatric threat trajectories after SARS-CoV-2 an infection: an evaluation of 2-year retrospective cohort research together with 1 284 437 sufferers. Lancet Psychiatry 9, 815–827 (2022).
Reiken, S. et al. Alzheimer’s-like signaling in brains of COVID-19 sufferers. Alzheimers Dement. 18, 955–965 (2022).
Charnley, M. et al. Neurotoxic amyloidogenic peptides within the proteome of SARS-COV2: potential implications for neurological signs in COVID-19. Nat. Commun. 13, 3387 (2022).
Visser, D. et al. Lengthy COVID is related to intensive in-vivo neuroinflammation on [18F]DPA-714 PET. Preprint at medRxiv (2022).
Guedj, E. et al. 18F-FDG mind PET hypometabolism in sufferers with lengthy COVID. Eur. J. Nucl. Med. Mol. Imaging 48, 2823–2833 (2021).
Hugon, J. et al. Cognitive decline and brainstem hypometabolism in lengthy COVID: a case collection. Mind Behav. 12, e2513 (2022).
Apple, A. C. et al. Threat components and irregular cerebrospinal fluid affiliate with cognitive signs after delicate COVID-19. Ann. Clin. Transl Neurol. 9, 221–226 (2022).
Douaud, G. et al. SARS-CoV-2 is related to modifications in mind construction in UK Biobank. Nature 604, 697–707 (2022).
Peluso, M. J. et al. SARS-CoV-2 and mitochondrial proteins in neural-derived exosomes of COVID-19. Ann. Neurol. 91, 772–781 (2022).
Villaume, W. A. Marginal BH4 deficiencies, iNOS, and self-perpetuating oxidative stress in post-acute sequelae of Covid-19. Med. Hypotheses 163, 110842 (2022).
Bitirgen, G. et al. Corneal confocal microscopy identifies corneal nerve fibre loss and elevated dendritic cells in sufferers with lengthy COVID. Br. J. Ophthalmol. (2021).
Barros, A. et al. Small fiber neuropathy within the cornea of Covid-19 sufferers related to the technology of ocular floor illness. Ocul. Surf. 23, 40–48 (2022).
Bitirgen, G. et al. Irregular quantitative pupillary gentle responses following COVID-19. Int. Ophthalmol. (2022).
Mardin, C. Y. et al. Potential affect of purposeful energetic GPCR-autoantibodies on retinal microcirculation in long-COVID. Make investments. Ophthalmol. Vis. Sci. 63, 3315–F0124 (2022).
Zhang, B.-Z. et al. SARS-CoV-2 infects human neural progenitor cells and mind organoids. Cell Res. 30, 928–931 (2020).
Sen, S. et al. Retinal manifestations in sufferers with SARS-CoV-2 an infection and pathogenetic implications: a scientific overview. Int. Ophthalmol. 42, 323–336 (2022).
Frere, J. J. et al. SARS-CoV-2 an infection in hamsters and people ends in lasting and distinctive systemic perturbations submit restoration. Sci. Transl Med. 14, eabq3059 (2022).
Rutkai, I. et al. Neuropathology and virus in mind of SARS-CoV-2 contaminated non-human primates. Nat. Commun. 13, 1745 (2022).
Committee on the Diagnostic Standards for Myalgic Encephalomyelitis/Power Fatigue Syndrome, Board on the Well being of Choose Populations, & Institute of Drugs. Past Myalgic Encephalomyelitis/Power Fatigue Syndrome: Redefining an Sickness (Nationwide Academies Press, 2015).
Bateman, L. et al. Myalgic encephalomyelitis/power fatigue syndrome: necessities of analysis and administration. Mayo Clin. Proc. 96, 2861–2878 (2021).
The ME Affiliation. Index of ME/CFS revealed analysis – Nov 2022. 224 Index of ME/CFS Printed Analysis. The ME Affiliation (2022).
Seltzer, J. & Thomas, J. ME Analysis Abstract 2019 (The ME Affiliation, 2019).
Wong, T. L. & Weitzer, D. J. Lengthy COVID and myalgic encephalomyelitis/power fatigue syndrome (ME/CFS)-a systemic overview and comparability of scientific presentation and symptomatology. Med. (Kaunas.) 57, 418 (2021).
Twomey, R. et al. Power fatigue and postexertional malaise in individuals residing with Lengthy COVID: an observational examine. Phys. Ther. 102, pzac005 (2022).
Vernon, S. D. et al. Orthostatic problem causes distinctive symptomatic, hemodynamic and cognitive responses in Lengthy COVID and myalgic encephalomyelitis/power fatigue syndrome. Entrance. Med. 9, 917019 (2022).
Lam, M. H.-B. et al. Psychological morbidities and power fatigue in extreme acute respiratory syndrome survivors: long-term follow-up. Arch. Intern. Med. 169, 2142–2147 (2009).
Keller, B. A., Pryor, J. L. & Giloteaux, L. Incapacity of myalgic encephalomyelitis/power fatigue syndrome sufferers to breed VO2peak signifies purposeful impairment. J. Transl Med. 12, 104 (2014).
Saha, A. Ok. et al. Erythrocyte deformability as a possible biomarker for power fatigue syndrome. Blood 132, 4874 (2018).
Díaz-Resendiz, Ok. J. G. et al. Lack of mitochondrial membrane potential (ΔΨm) in leucocytes as post-COVID-19 sequelae. J. Leukoc. Biol. 112, 23–29 (2022).
Pozzi, A. COVID-19 and mitochondrial non-coding RNAs: new insights from revealed knowledge. Entrance. Physiol. 12, 805005 (2022).
Guntur, V. P. et al. Signatures of mitochondrial dysfunction and impaired fatty acid metabolism in plasma of sufferers with post-acute sequelae of COVID-19 (PASC). Metabolites 12, 1026 (2022).
Paul, B. D., Lemle, M. D., Komaroff, A. L. & Snyder, S. H. Redox imbalance hyperlinks COVID-19 and myalgic encephalomyelitis/power fatigue syndrome. Proc. Natl Acad. Sci. USA 118, e2024358118 (2021).
Wright, J., Astill, S. L. & Sivan, M. The connection between bodily exercise and Lengthy COVID: a cross-sectional examine. Int. J. Environ. Res. Public Well being 19, 5093 (2022).
Heerdt, P. M., Shelley, B. & Singh, I. Impaired systemic oxygen extraction lengthy after delicate COVID-19: potential perioperative implications. Br. J. Anaesth. 128, e246–e249 (2022).
Novak, P. et al. Multisystem involvement in post-acute sequelae of coronavirus illness 19. Ann. Neurol. 91, 367–379 (2022).
Holmes, E. et al. Incomplete systemic restoration and metabolic phenoreversion in post-acute-phase nonhospitalized COVID-19 sufferers: implications for evaluation of post-acute COVID-19 syndrome. J. Proteome Res. 20, 3315–3329 (2021).
van Campen, C. L. M. C. & Visser, F. C. Orthostatic intolerance in long-haul COVID after SARS-CoV-2: a case-control comparability with post-EBV and insidious-onset myalgic encephalomyelitis/power fatigue syndrome sufferers. Healthcare 10, 2058 (2022).
van Campen, C. L. M. C. & Visser, F. C. Lengthy-Haul COVID sufferers: prevalence of POTS are lowered however cerebral blood movement abnormalities stay irregular with longer illness period. Healthcare 10, 2105 (2022).
Nunes, J. M., Kruger, A., Proal, A., Kell, D. B. & Pretorius, E. The prevalence of hyperactivated platelets and fibrinaloid microclots in myalgic encephalomyelitis/power fatigue syndrome (ME/CFS). Prescription drugs 15, 931 (2022).
Hoad, A., Spickett, G., Elliott, J. & Newton, J. Postural orthostatic tachycardia syndrome is an under-recognized situation in power fatigue syndrome. QJM 101, 961–965 (2008).
Shaw, B. H. et al. The face of postural tachycardia syndrome – insights from a big cross‐sectional on-line group‐primarily based survey. J. Intern. Med. 286, 438–448 (2019).
Raj, S. R. et al. Postural orthostatic tachycardia syndrome (POTS): priorities for POTS care and analysis from a 2019 Nationwide Institutes of Well being knowledgeable consensus assembly – half 2. Auton. Neurosci. Fundamental. Clin. 235, 102836 (2021).
Oaklander, A. L. et al. Peripheral neuropathy evaluations of sufferers with extended Lengthy COVID. Neurol. Neuroimmunol. Neuroinflamm. 9, e1146 (2022).
Larsen, N. W. et al. Characterization of autonomic symptom burden in lengthy COVID: a world survey of two,314 adults. Entrance. Neurol. 13, 1012668 (2022).
Weinstock, L. B. et al. Mast cell activation signs are prevalent in Lengthy-COVID. Int. J. Infect. Dis. 112, 217–226 (2021).
Boneva, R. S. et al. Endometriosis as a comorbid situation in power fatigue syndrome (CFS): secondary evaluation of information from a CFS case-control examine. Entrance. Pediatr. 7, 195 (2019).
Bragée, B. et al. Indicators of intracranial hypertension, hypermobility, and craniocervical obstructions in sufferers with myalgic encephalomyelitis/power fatigue syndrome. Entrance. Neurol. 11, (2020).
Medina-Perucha, L. et al. Self-reported menstrual alterations throughout the COVID-19 syndemic in Spain: a cross-sectional examine. Int. J. Womens Well being 14, 529–544 (2022).
Ding, T. et al. Evaluation of ovarian harm related to COVID-19 illness in reproductive-aged ladies in Wuhan, China: an observational examine. Entrance. Med. 8, 635255 (2021).
Sharp, G. C. et al. The COVID-19 pandemic and the menstrual cycle: analysis gaps and alternatives. Int. J. Epidemiol. (2021).
Khan, S. M. et al. SARS-CoV-2 an infection and subsequent modifications within the menstrual cycle amongst members within the Arizona CoVHORT examine. Am. J. Obstet. Gynecol. 226, 270–273 (2022).
Harlow, B. L., Signorello, L. B., Corridor, J. E., Dailey, C. & Komaroff, A. L. Reproductive correlates of power fatigue syndrome. Am. J. Med. 105, 94S–99S (1998).
Thomas, N., Gurvich, C., Huang, Ok., Gooley, P. R. & Armstrong, C. W. The underlying intercourse variations in neuroendocrine diversifications related to myalgic encephalomyelitis power fatigue syndrome. Entrance. Neuroendocrinol. 66, 100995 (2022).
Boneva, R. S., Lin, J.-M. S. & Unger, E. R. Early menopause and different gynecologic threat indicators for power fatigue syndrome in ladies. Menopause 22, 826–834 (2015).
Kresch, E. et al. COVID-19 endothelial dysfunction could cause erectile dysfunction: histopathological, immunohistochemical, and ultrastructural examine of the human penis. World J. Mens Well being 39, 466–469 (2021).
Maleki, B. H. & Tartibian, B. COVID-19 and male reproductive perform: a potential, longitudinal cohort examine. Copy 161, 319–331 (2021).
Yu, J. Z. et al. Lung perfusion disturbances in nonhospitalized post-COVID with dyspnea — a magnetic resonance imaging feasibility examine. J. Intern. Med. 292, 941–956 (2022).
Cho, J. L. et al. Quantitative chest CT evaluation of small airways illness in post-acute SARS-CoV-2 an infection. Radiology 304, 185–192 (2022).
Vijayakumar, B. et al. Immuno-proteomic profiling reveals aberrant immune cell regulation within the airways of people with ongoing post-COVID-19 respiratory illness. Immunity 55, 542–556.e5 (2022).
Littlefield, Ok. M. et al. SARS-CoV-2-specific T cells affiliate with irritation and lowered lung perform in pulmonary post-acute sequalae of SARS-CoV-2. PLOS Pathog. 18, e1010359 (2022).
Meringer, H. & Mehandru, S. Gastrointestinal post-acute COVID-19 syndrome. Nat. Rev. Gastroenterol. Hepatol. 19, 345–346 (2022).
König, R. S. et al. The intestine microbiome in myalgic encephalomyelitis (ME)/power fatigue syndrome (CFS). Entrance. Immunol. 12, 628741 (2022).
Zuo, T. et al. Depicting SARS-CoV-2 faecal viral exercise in affiliation with intestine microbiota composition in sufferers with COVID-19. Intestine 70, 276–284 (2021).
Zollner, A. et al. Postacute COVID-19 is characterised by intestine viral antigen persistence in inflammatory bowel illnesses. Gastroenterology 163, 495–506.e8 (2022).
Giron, L. B. et al. Markers of fungal translocation are elevated throughout post-acute sequelae of SARS-CoV-2 and induce NF-κB signaling. JCI Perception (2022).
Jason, L. A. et al. COVID-19 signs over time: evaluating long-haulers to ME/CFS. Fatigue Biomed. Well being Behav. 9, 59–68 (2021).
Tran, V.-T., Porcher, R., Pane, I. & Ravaud, P. Course of submit COVID-19 illness signs over time within the ComPaRe lengthy COVID potential e-cohort. Nat. Commun. 13, 1812 (2022).
Walker, A., Kelly, C., Pottinger, G. & Hopkins, C. Parosmia — a standard consequence of covid-19. BMJ 377, e069860 (2022).
Jamal, S. M. et al. Potential analysis of autonomic dysfunction in post-acute sequela of COVID-19. J. Am. Coll. Cardiol. 79, 2325–2330 (2022).
Stavileci, B., Özdemir, E., Özdemir, B., Ereren, E. & Cengiz, M. De-novo improvement of fragmented QRS throughout a six-month follow-up interval in sufferers with COVID-19 illness and its cardiac results. J. Electrocardiol. 72, 44–48 (2022).
Grist, J. T. et al. Lung abnormalities depicted with hyperpolarized 129Xe MRI in sufferers with lengthy COVID. Radiology 305, 709–717 (2022).
US ME/CFS Clinician Coalition. Testing Suggestions for Suspected ME/CFS (US ME/CFS Clinician Coalition, 2021).
Galán, M. et al. Persistent overactive cytotoxic immune response in a Spanish cohort of people with long-COVID: identification of diagnostic biomarkers. Entrance. Immunol. 13, 848886 (2022).
Grandjean, D. et al. Screening for SARS-CoV-2 persistence in Lengthy COVID sufferers utilizing sniffer canine and smells from axillary sweats samples. Clin. Trials 12, 2 (2022).
Pifarré, F. et al. Using oxygen as a attainable screening biomarker for the analysis of power fatigue. Apunt. Sports activities Med 57, 100379 (2022).
Jason, L. A., Kalns, J., Richarte, A., Katz, B. Z. & Torres, C. Saliva fatigue biomarker index as a marker for extreme myalgic encephalomyelitis/power fatigue syndrome in a group primarily based pattern. Fatigue Biomed. Well being Behav. 9, 189–195 (2021).
Esfandyarpour, R., Kashi, A., Nemat-Gorgani, M., Wilhelmy, J. & Davis, R. W. A nanoelectronics-blood-based diagnostic biomarker for myalgic encephalomyelitis/power fatigue syndrome (ME/CFS). Proc. Natl Acad. Sci. USA 116, 10250–10257 (2019).
Nkiliza, A. et al. Intercourse-specific plasma lipid profiles of ME/CFS sufferers and their affiliation with ache, fatigue, and cognitive signs. J. Transl Med. 19, 370 (2021).
Bolton, M. J., Chapman, B. P. & Van Marwijk, H. Low-dose naltrexone as a therapy for power fatigue syndrome. BMJ Case Rep. 13, e232502 (2020).
Pitt, B., Tate, A. M., Gluck, D., Rosenson, R. S. & Goonewardena, S. N. Repurposing low-dose naltrexone (LDN) for the prevention and therapy of immunothrombosis in COVID-19. Eur. Coronary heart J. Cardiovasc. Pharmacother. (2022).
Alper, Ok. Case report: famotidine for neuropsychiatric signs in COVID-19. Entrance. Med. 7, 614393 (2020).
Hohberger, B. et al. Case report: neutralization of autoantibodies focusing on G-protein-coupled receptors improves capillary impairment and fatigue signs after COVID-19 an infection. Entrance. Med. 8, 754667 (2021).
Wang, C. et al. Lengthy COVID: the character of thrombotic sequelae determines the need of early anticoagulation. Entrance. Cell. Infect. Microbiol. 12, 861703 (2022).
The ME Affiliation. A brand new therapy for Lengthy Covid? The ME Affiliation 2021/10/a-new-treatment-for-long-covid/ (2021).
Tölle, M. et al. Myalgic encephalomyelitis/power fatigue syndrome: efficacy of repeat immunoadsorption. J. Clin. Med. 9, E2443 (2020).
Wooden, E., Corridor, Ok. H. & Tate, W. Position of mitochondria, oxidative stress and the response to antioxidants in myalgic encephalomyelitis/power fatigue syndrome: a attainable method to SARS-CoV-2 ‘long-haulers’? Power Dis. Transl Med. 7, 14–26 (2020).
NICE. Myalgic encephalomyelitis (or encephalopathy)/power fatigue syndrome: analysis and administration. NICE (2021).
World Well being Group. Assist for Rehabilitation Self-Administration After COVID-19 Associated Sickness (WHO, 2021).
CDC. Remedy of ME/CFS | Myalgic encephalomyelitis/power fatigue syndrome (ME/CFS). CDC (2021).
Geng, L. N., Bonilla, H. F., Shafer, R. W., Miglis, M. G. & Yang, P. C. Case report of breakthrough lengthy COVID and using nirmatrelvir-ritonavir. Preprint at (2022).
Xie, Y., Choi, T. & Al-Aly, Z. Nirmatrelvir and the danger of post-acute sequelae of COVID-19. Preprint at medRxiv (2022).
Charfeddine, S. et al. Sulodexide within the therapy of sufferers with lengthy COVID 19 signs and endothelial dysfunction: the outcomes of TUN-EndCOV examine. Arch. Cardiovasc. Dis. Suppl. 14, 127 (2022).
Thomas, R. et al. A randomised, double-blind, placebo-controlled trial evaluating concentrated phytochemical-rich dietary capsule along with a probiotic capsule on scientific outcomes amongst people with COVID-19 — the UK Phyto-V examine. COVID 2, 433–449 (2022).
Zhang, L. et al. Intestine microbiota-derived synbiotic components (SIM01) as a novel adjuvant remedy for COVID-19: an open-label pilot examine. J. Gastroenterol. Hepatol. 37, 823–831 (2022).
Liu, L. D. & Duricka, D. L. Stellate ganglion block reduces signs of Lengthy COVID: a case collection. J. Neuroimmunol. 362, 577784 (2022).
Belcaro, G. et al. Preventive results of Pycnogenol® on cardiovascular threat components (together with endothelial perform) and microcirculation in topics recovering from coronavirus illness 2019 (COVID-19). Minerva Med. 113, 300–308 (2022).
Crooks, V., Waller, S., Smith, T. & Hahn, T. J. Using the Karnofsky Efficiency Scale in figuring out outcomes and threat in geriatric outpatients. J. Gerontol. 46, M139–M144 (1991).
Ledford, H. Lengthy-COVID remedies: why the world remains to be ready. Nature 608, 258–260 (2022).
Toogood, P. L., Clauw, D. J., Phadke, S. & Hoffman, D. Myalgic encephalomyelitis/power fatigue syndrome (ME/CFS): the place will the medicine come from? Pharmacol. Res. 165, 105465 (2021).
US ME/CFS Clinician Coalition. ME/CFS Remedy Suggestions (US ME/CFS Clinician Coalition, 2021).
Taquet, M., Dercon, Q. & Harrison, P. J. Six-month sequelae of post-vaccination SARS-CoV-2 an infection: a retrospective cohort examine of 10,024 breakthrough infections. Mind Behav. Immun. 103, 154–162 (2022).
Workplace for Nationwide Statistics. Self-reported lengthy COVID after an infection with the Omicron variant within the UK: 6 Could 2022. Workplace for Nationwide Statistics (2022).
Tsuchida, T. et al. Relationship between modifications in signs and antibody titers after a single vaccination in sufferers with Lengthy COVID. J. Med. Virol. 94, 3416–3420 (2022).
VA COVID-19 Observational Analysis Collaboratory. Burden of PCR-confirmed SARS-CoV-2 reinfection within the U.S. Veterans Administration, March 2020 – January 2022. Preprint at medRxiv (2022).
Bowe, B., Xie, Y. & Al-Aly, Z. Acute and postacute sequelae related to SARS-CoV-2 reinfection. Nat. Med. (2022).
Blomberg, J., Gottfries, C.-G., Elfaitouri, A., Rizwan, M. & Rosén, A. An infection elicited autoimmunity and myalgic encephalomyelitis/power fatigue syndrome: an explanatory mannequin. Entrance. Immunol. 9, 229 (2018).
Cauchemez, S. & Bosetti, P. A reconstruction of early cryptic COVID unfold. Nature 600, 40–41 (2021).
CDC. Estimated COVID-19 burden. Facilities for Illness Management and Prevention (2020).
Kucirka, L. M., Lauer, S. A., Laeyendecker, O., Boon, D. & Lessler, J. Variation in false-negative charge of reverse transcriptase polymerase chain response–primarily based SARS-CoV-2 checks by time since publicity. Ann. Intern. Med. 173, 262–267 (2020).
Levine-Tiefenbrun, M. et al. SARS-CoV-2 RT-qPCR take a look at detection charges are related to affected person age, intercourse, and time since analysis. J. Mol. Diagn. 24, 112–119 (2022).
Jarvis, Ok. F. & Kelley, J. B. Temporal dynamics of viral load and false damaging charge affect the degrees of testing essential to fight COVID-19 unfold. Sci. Rep. 11, 9221 (2021).
Dattner, I. et al. The position of kids within the unfold of COVID-19: utilizing family knowledge from Bnei Brak, Israel, to estimate the relative susceptibility and infectivity of kids. PLoS Comput. Biol. 17, e1008559 (2021).
Langeland, N. & Cox, R. J. Are low SARS-CoV-2 viral hundreds in contaminated kids missed by RT-PCR testing? Lancet Reg. Well being Eur. 5, 100138 (2021).
Van Elslande, J. et al. Longitudinal follow-up of IgG anti-nucleocapsid antibodies in SARS-CoV-2 contaminated sufferers as much as eight months after an infection. J. Clin. Virol. 136, 104765 (2021).
Liu, W. et al. Predictors of nonseroconversion after SARS-CoV-2 an infection. Emerg. Infect. Dis. 27, 2454–2458 (2021).
Toh, Z. Q. et al. Comparability of seroconversion in kids and adults with delicate COVID-19. JAMA Netw. Open 5, e221313 (2022).
Peterson, T. M., Peterson, T. W., Emerson, S., Meredyth, A. Evans, E. R. & Jason, L. A. Protection of CFS inside U.S. medical colleges. Univers. J. Public Well being 1, 177–179 (2013).
Rowe, P. C. et al. Orthostatic intolerance and power fatigue syndrome related to Ehlers-Danlos syndrome. J. Pediatr. 135, 494–499 (1999).
Nguyen, T. et al. Novel characterisation of mast cell phenotypes from peripheral blood mononuclear cells in power fatigue syndrome/myalgic encephalomyelitis sufferers. Asian Pac. J. Allergy Immunol. 35, 75–81 (2017).
Wagner, C., Isenmann, S., Ringendahl, H. & Haensch, C.-A. Anxiousness in sufferers with postural tachycardia syndrome (POTS). Fortschr. Neurol. Psychiatr. 80, 458–462 (2012).
Grayson, D. A., Mackinnon, A., Jorm, A. F., Creasey, H. & Broe, G. A. Merchandise bias within the middle for epidemiologic research melancholy scale: results of bodily problems and incapacity in an aged group pattern. J. Gerontol. Ser. B 55, P273–P282 (2000).
Twisk, F. N. M. & Maes, M. A overview on cognitive behavorial remedy (CBT) and graded train remedy (GET) in myalgic encephalomyelitis (ME) / power fatigue syndrome (CFS): CBT/GET will not be solely ineffective and never evidence-based, but additionally doubtlessly dangerous for a lot of sufferers with ME/CFS. Neuro Endocrinol. Lett. 30, 284–299 (2009).
Vink, M. & Vink-Niese, F. Is it helpful to query the restoration behaviour of sufferers with ME/CFS or Lengthy COVID? Healthcare 10, 392 (2022).
Dysautonomia Worldwide. What’s dysautonomia? Dysautonomia Worldwide (2022).
CDC. Epidemiology | Presentation and scientific course | Healthcare suppliers | Myalgic encephalomyelitis/power fatigue syndrome (ME/CFS). CDC (2021).
Sørensen, A. I. V. et al. A nationwide questionnaire examine of post-acute signs and well being issues after SARS-CoV-2 an infection in Denmark. Nat. Commun. 13, 4213 (2022).
Berg, S. Ok. et al. Lengthy COVID signs in SARS-CoV-2-positive kids aged 0–14 years and matched controls in Denmark (LongCOVIDKidsDK): a nationwide, cross-sectional examine. Lancet Little one Adolesc. Well being 6, 614–623 (2022).
Morrow, A. Ok. et al. Lengthy-term COVID 19 sequelae in adolescents: the overlap with orthostatic intolerance and ME/CFS. Curr. Pediatr. Rep. 10, 31–44 (2022).
Cooper, S. et al. Lengthy COVID-19 liver manifestation in kids. J. Pediatr. Gastroenterol. Nutr. (2022).
Kompaniyets, L. Submit–COVID-19 signs and situations amongst kids and adolescents — United States, March 1, 2020–January 31, 2022. MMWR Morb. Mortal. Wkly Rep. 71, 993–999 (2022).
Edlow, A. G., Castro, V. M., Shook, L. L., Kaimal, A. J. & Perlis, R. H. Neurodevelopmental outcomes at 1 yr in infants of moms who examined optimistic for SARS-CoV-2 throughout being pregnant. JAMA Netw. Open 5, e2215787 (2022).
Morand, A. et al. Related patterns of [18F]-FDG mind PET hypometabolism in paediatric and grownup sufferers with lengthy COVID: a paediatric case collection. Eur. J. Nucl. Med. Mol. Imaging 49, 913–920 (2022).
Heiss, R. et al. Pulmonary dysfunction after pediatric COVID-19. Radiology (2022).